Clinical Trials Logo

Clinical Trial Summary

Assessment of the role of volumetric MRI in evaluation of different types of migraine .


Clinical Trial Description

Migraine is a common condition that many people experience during their lives. Evolving data reported that migraine patients have increased risk of developing silent brain lesions, such as white matter lesions and volumetric changes in both grey and white matter found on MRI . These changes have been first investigated with CT scans which reported cerebral edema, atrophy and ischemia . With the advent of MRI and high-resolution devices, the most commonly reported structural changes were white matter lesions . Volumetric brain MRI is the tool segments and measures volumes of the key brain structures-hippocampus, ventricles and other structures-and compares the volumes to standard normal values based on age, gender and cranial volume. This information helps assess neurological conditions and neurodegenerative diseases . - In migraine patients ,Volumetric MRI techniques allow better assessment of WMLs and may provide a different comprehension of structural aspects related to the migraine pathophysiology. The identification of migraineurs' brain structural alterations through non-invasive neuroimaging methods and the use of accessible and easy to-use software brings new perspectives on the assessment of the impact of this condition in central nervous system macro-architecture . - In previous studies, structural brain changes in migraineurs were assessed by an automated segmentation using (Free Surfer) method . In our study, we aim to investigate these total and segmental structural changes of brain volume in migraine patients; as well as white matter lesions, in comparison to healthy controls, and in patients with episodic migraine in comparison to chronic type of migraine using another automated tissue segmentation (Vol brain) method. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06077448
Study type Observational
Source Assiut University
Contact
Status Not yet recruiting
Phase
Start date October 10, 2023
Completion date February 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A